Aviron

Founded in 1992 by J. Leighton Read, Aviron was a Mountain View, California biopharmaceutical company focused on the research and development of vaccines and antiviral agents for infectious diseases. The enterprise specifically developed specialized antiviral treatments targeting Hepatitis C, alongside its broader clinical portfolio of preventative medicines and the flagship nasal influenza vaccine FluMist. Operating initially as a publicly traded entity on the NASDAQ exchange under the ticker AVIR, the firm scaled its biotechnology operations through venture capital and public market investments. The company ultimately reached a valuation of approximately $1.5 billion when it was acquired by the pharmaceutical corporation MedImmune in a stock transaction announced in late 2001 and completed in early 2002. Following this major corporate merger, the organization's influenza vaccine successfully secured regulatory approval from the FDA for broader commercial distribution in 2003.